
# Curriculum Vitae - Sara Gandini

### Academic information

- 2004 **PHD IN CANCER STUDIES** at the University of Birmingham (Public Health), UK. Thesis: "Meta-Analysis in Cancer Epidemiology".
- 1995 MASTER OF SCIENCE IN BIOMETRY at the Department of Applied Statistics at the University of Reading (UK). Thesis in Epidemiology: "Ordered categorical modelling of categorical data from the Scottish Heart Health Study".
- Doctor in **STATISTICS** at the University of Bologna, with the score **110/110 WITH HONOURS** (first class degree). "Corso di laurea in Scienze statistiche ed economiche". Thesis in statistical methods: "Choice of logistic models".

August 2015: Total citations without self-citations: 8619; average cit. per year: 311; h-index=41 (overall). More than 120 publication in peer reviews journals.



Working experiences

Since 2009 Employed as Senior Staff Scientist (Vice-Director) at the division of Epidemiology and Biostatistics Division in IEO, Milan (Italy).

2014 Statistical consultant at Multimedica ethical committee, Milan, Italy.

2013 Member of independent monitor committee of an Italian phase III trial (TAMo1: dose tamoxifen).

2010 Member of an independent monitor committee of a trial organized by Novartis Vaccines in India and Pakistan.

2002-2009 Employed as Staff Scientist in Epidemiology and Biostatistics Division at IEO, Milan (Italy).

1997-2002 Employed as Scientist in Epidemiology and Biostatistics Division at the European Institute of IEO, Milan (Italy).

1996 Fellow at the Division of Epidemiology and Biostatistics of IEO ('Associazione Italiana per la ricerca sul cancro' grant- PI Boyle P.).

1995 Assistant in biometrics courses at the University of Reading.

1993-1994 Teacher of Mathematics in high school in Italy.

#### Lecturer

2015-2016 Master at the University of Parma.

In 2015 at a Master Course in "Applied research" organized by University of Milan ("Dipartimento di Scienze della Salute & Centro di Ricerca e Intervento sui Processi Decisionali") in collaboration with the European Institute of Oncology (IEO).

2014 Lecturer for 'The European School of Oncology (ESO)' in Romania.

Since 2009 Lecturer in Statistical methods in medical research at IEO.

Since 2008 at Master Courses of IMI (Italian Melanoma Intergroup): 'Statistics in medicine' for a Master in 'Management of melanoma patient: from research to therapy', IMI.

#### Scientific societies

Since 2014 Member of EORTC Steering committee of the Melanoma group and Chair of the Melanoma Epi-subgroup.

Since 2014 <u>President of Euroskin</u> independent non-profit scientific society: www.euroskin.eu

Since 2008 Member of the scientific faculty of Italian Melanoma Intergroup (IMI) congresses.

## **Awards**

2008 BRUNO MARTINETTO AWARD for Research in Chemoprevention.

### Grants as PI

**2014 Associazione Italiana per la Ricerca sul Cancro (AIRC)** Principal investigator of a project about Vitamin D on microbiome in colorectal cancer: Pilot trial

**2013 Fondazione Umberto Veronesi (FUV)** Principal investigator of a project about Vitamin D on microbiome in colorectal cancer: case-control study

#### 2010 FUV:

Principal investigator of a project on "Biomarkers studies on stage II melanoma patients treated with Vitamin D".

### 2010 Fondazione Grazia Focacci:

Principal investigator of a project on "Biomarkers studies on stage II melanoma patients treated with Vitamin D".

## Grants as collaborator

**2015 National Cancer Institute:** "Alternative Dosing of Exemestane in Postmenopausal Women with Stage o-II ER-Positive Breast Cancer: a Randomized Presurgical Trial". Protocol Lead Organization: MD Anderson, in collaboration with Division of Cancer Prevention and Genetics (IEO)

**2015 Health Italian Ministry (Bando Ricerca Finalizzata)**: "Low adiponectin levels as independent risk marker for breast cancer in high risk postmenopausal women"; in collaboration with Division of Cancer Prevention and Genetics (IEO).

**2015** Health Italian Ministry (Bando Ricerca Finalizzata): "Prognostic and predictive values of tumor infiltrating lymphocytes in patients with ductal carcinoma in situ of the breast."; in collaboration with Division of Cancer Prevention and Genetics (IEO).

**2015** "Ricerca Scientifica dell'Ente Ospedaliero Cantonale (ABREOC)": multicentre study to evaluate the effect of counselling for breast cancer patients facing treatment or screening decisions.

**2015** Health Italian Ministry (Bando Ricerca Finalizzata): "Prognostic and predictive values of tumor infiltrating lymphocytes in patients with ductal carcinoma in situ of the breast."; in collaboration with Division of Cancer Prevention and Genetics (IEO).

**2014 ERA-NET on Translational Cancer Research (TRANSCAN):** "A phase II study with metformin in breast cancer survivors at higher risk for recurrence" in collaboration with Division of Cancer Prevention and Genetics (IEO)"

**2013 Regione Toscana:** "MelaBlock: Randomized clinical trial for melanoma stage II patients to assess effect of  $\beta$ -adrenoceptor blockers on melanoma recurrence" in collaboration with University of Florence.

**2012 Fondazione Umberto Veronesi:** "How to evaluate lymph-nodes of Cloquet." In collaboration with IEO Melanoma division.

**2012 European Space Agency (ESA):** Research Using Concordia Antarctic Station as Human Exploration Analogue (AO-11-Concordia). Team member for the project: "Impact of Vitamin D supplementation on health markers at Concordia (VITAD)"

**2010 Istituto Oncologico Romagnolo**: "Save the skin project" in collaboration with "Istituto Oncologico Romagnolo" and Skin Cancer Unit of "IRCCS - Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST)"

### International Collaborations

Since 2009 Senior research fellow at the International Prevention Research Institute (iPRI), Lyon (France)

2000-2008 participation at International Working Groups at the International Agency Research for Cancer (IARC), Lyon (France):

Artificial light and skin cancer;

- All avoidable causes of cancer;
- Cancer Following the Chernobyl Accident;
- Burden of cancer from Asbestos Exposure;
- Vitamin D and human cancer;
- European cancer mortality atlas.

## Languages knowledge

1994 IELTS (International English Test). Scholastic knowledge of French.

#### Courses

- 2015 IRST Meldola (Italy) about "Data analysis of next-generation sequencing";
- 2012 At the University of Milan (Italy) about "Adaptive design";
- 2006 At the University of Edinburgh (UK) about "Mixed models analysis of medical data using SAS";
- 2001 At the University of Brescia (Italy) about "Introduction to Genetic Epidemiology";
- 1998 At the University in London (UK) about "Meta-analysis in clinical practice";
- 1997 At Mario Negri Institute (Milan, Italy) about "Current issues in clinical Trials methodology" by Prof Stuart Pocock (University of London);
- 1996 At the New England Epidemiology Institute, Tuft University, Boston (USA) about "Epidemiology and Meta-analysis".

# Stages

- 1996 Harvard School of Public Health (Boston, USA) in the division of Epidemiology with Dr. Alexander Walker.
- 1997 Center for research of University of Montreal and the Hôtel-Dieu hospital (Montreal, Canada) in the Unit of Epidemiology research.